Odyssey Therapeutics

Odyssey Therapeutics

Odyssey Therapeutics, recognized on the 2022 Endpoints 11 list, pioneers next-generation precision immunomodulators and oncology medicines, utilizing advanced drug discovery technologies and strategic collaborations.

Services

Odyssey Therapeutics specializes in developing next-generation precision immunomodulators and oncology medicines. The company utilizes a highly integrated drug hunting engine that combines established and emerging drug discovery technologies. They focus on immunology and oncology targets that have high clinical and commercial potential, including those previously labeled as 'undruggable.' Their services encompass a comprehensive drug discovery and development platform merging computational and experimental technologies.

History

Founded in late 2021, Odyssey Therapeutics has quickly established itself as a promising player in the biotechnology sector. In a short span, the company has raised $487 million in capital, including a $101 million Series C financing round closed in December 2023. In 2022, Odyssey was named to the Endpoints 11 list by Endpoints News, recognizing it as one of the most promising private biotechnology companies.

Strategic Collaborations

Odyssey Therapeutics entered a strategic research collaboration with Janssen Pharmaceutica NV. This collaboration focuses on jointly discovering and optimizing small molecule medicines using advanced techniques such as artificial intelligence, machine learning, and computational chemistry. Additionally, Odyssey is a member of the Cancer Dependency Map (DepMap) 2.0 consortium sponsored by the BROAD institute.

Research and Development

The company's R&D efforts are robust, rapidly advancing multiple pre-clinical programs in immunology and oncology. They employ a platform approach that includes CRISPR-based functional genomic screening, CRISPR-Cas9 base-editing, and advanced cell culture and in vivo models of tumor biology. Odyssey also utilizes a small molecule in silico discovery platform for hit identification through multiparameter-based lead optimization. Their proprietary small molecule libraries facilitate hit finding and target-centric screening capabilities.

Locations

Odyssey Therapeutics is headquartered in Boston, with additional locations in San Diego, Ann Arbor, and Frankfurt. These locations are instrumental in supporting the company's wide range of drug discovery and development activities.

Companies similar to Odyssey Therapeutics